Career Center


Pros and Cons: Working in Small Life Sciences Companies vs. Large Organizations

Is your dream job with a large organization or a small company? It’s common for life sciences professionals to have a preference one way or the other when considering employment opportunities. While many people might have a primary reason for desiring to work at a small company or a large organization, most individuals haven’t really compared the differences and the implications on their career. Are you impressed by large established organizations? Or, do you seek out innovative start-ups and small companies? To help with your career planning, we’ve compiled a list of the major pros and cons when working in small companies versus large organizations!

Learn More

A Novel Approach to Real-Time Monitoring of Antibody Titer in a Fed-Batch Bioreactor Run

The titer of an antibody being expressed in a stirred bioreactor is usually measured offline using a process that involves removing an aliquot aseptically from the bioreactor, centrifuging the aliquot, and analyzing the resulting supernatant. The supernatant is analyzed either by bio-layer interferometry (BLI), Protein A HPLC, or ELISA. Such an approach may limit throughput, workflow, and efficiency. Aragen evaluated a prototype chromatography-based device that is directly connected to a bioreactor. Learn More

Fujifilm Diosynth Investing $55M to Build Gene Therapy Innovation Center in Texas

Fujifilm Diosynth Biotechnologies has announced the expansion of its gene therapy services with the addition of dedicated process and analytical development laboratories. As part of a capital investment of approximately $120 million in the gene therapy field by FUJIFILM Corporation, an investment of approximately $55 million USD will be made to establish a new Gene Therapy Innovation Center adjacent to the existing state-of-the-art cGMP gene therapy manufacturing facility in College Station, Texas. The Gene Therapy Innovation Center will be approximately 60,000 square feet and house state-of-the-art upstream, downstream and analytical development technologies. The facility will be operational in the fall of 2021. Learn More